Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - efavirenz,emtricitabine,tenofovir disoproxil fumarate -

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - sofosbuvir 400mg;  ;  ;  ; velpatasvir 100mg;  ;  ;   - tablet - 400mg/100mg - active: sofosbuvir 400mg       velpatasvir 100mg       excipient: copovidone croscarmellose sodium opadry ii pink 85f94644 magnesium stearate microcrystalline cellulose - indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - sofosbuvir 400mg;  ;  ;  ; velpatasvir 100mg;  ;  ;  ; voxilaprevir 100mg;   - film coated tablet - active: sofosbuvir 400mg       velpatasvir 100mg       voxilaprevir 100mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f170040 - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - bictegravir sodium 52.45mg equivalent to to 50 mg bictegravir;  ; emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 28.04mg equivalent to to 25 mg tenofovir alafenamide;   - film coated tablet - active: bictegravir sodium 52.45mg equivalent to to 50 mg bictegravir   emtricitabine 200mg         tenofovir alafenamide fumarate 28.04mg equivalent to to 25 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry brown 85f165072 - biktarvy is indicated for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are antiretroviral therapy (art)-na?ve or to replace the current antiretroviral regimen in those who are virologically-suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen at the start of therapy with no history of treatment failure, and no known substitutions associated with resistance to the individual components of biktarvy.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: hyprolose; lactose monohydrate; microcrystalline cellulose; silicon dioxide; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - stribild is indicated as a single tablet regimen for the treatment of hiv infection in treatment-na?ve adults. stribild is also indicated in certain virologically suppressed (hiv1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of stribild (tenofovir df, emtricitabine or elvitegravir). stribild is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg;   - film coated tablet - 25 mg - active: tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f120028 purified water - indicated for the treatment of chronic hepatitis b in adults.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 11.2mg equivalent to 10 mg tenofovir alafenamide;   - film coated tablet - 200mg/10mg - active: emtricitabine 200mg         tenofovir alafenamide fumarate 11.2mg equivalent to 10 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry grey 85f97517 - descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and adolescents aged 12 years and older with body weight at least 35 kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy. descovy is not for use in pre-exposure prophylaxis (prep)?.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 28mg equivalent to 25 mg tenofovir alafenamide;   - film coated tablet - 200mg/25mg - active: emtricitabine 200mg         tenofovir alafenamide fumarate 28mg equivalent to 25 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 85f105057 - descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and adolescents aged 12 years and older with body weight at least 35 kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy. descovy is not for use in pre-exposure prophylaxis (prep)?.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ; rilpivirine hydrochloride 27.5mg equivalent to rilpivirine free base 25 mg;  ; tenofovir disoproxil fumarate 300mg;  ;  ;   - film coated tablet - active: emtricitabine 200mg       rilpivirine hydrochloride 27.5mg equivalent to rilpivirine free base 25 mg   tenofovir disoproxil fumarate 300mg       excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry polysorbate 20 povidone pregelatinised maize starch purified water - eviplera is indicated for the treatment of hiv infection in treatment-na?ve adult patients with plasma hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy. eviplera is also indicated in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of resistance to any of the components of eviplera (tenofovir df, emtricitabine or rilpivirine).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 11.2 mg (equivalent: tenofovir alafenamide, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; iron oxide black - treatment of hiv-1 infection: descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy (see section 5.1 pharmacodynamic properties).,hiv-1 pre-exposure prophylaxis: descovy is indicated for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in at-risk adults and adolescents weighing at least 35 kg, excluding individuals at risk from receptive vaginal sex.